Nutritional Approaches to Late Toxicities of Adjuvant Chemotherapy in Breast Cancer Survivors

Journal of Nutrition

Volumn 133, Issue 11 SUPPL. 1, 2003, Pages

  Rock, Edwin ^a   DeMichele, Angela ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 14 Penn Tower   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Breast cancer; Chemotherapy; Nutrition; Survivorship

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANGELICA SINENSIS EXTRACT; ANTINEOPLASTIC AGENT; ASCORBIC ACID; BETA CAROTENE; CAPSAICIN; CIMICIFUGA RACEMOSA EXTRACT; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PLANT EXTRACT; PRIMROSE OIL; PROBUCOL; RAZOXANE; RETINOL; SELENIUM; THIOCTIC ACID; TRASTUZUMAB; TRICYCLIC ANTIDEPRESSANT AGENT; UBIQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN; ZINC;

ACUTE LEUKEMIA; ACUTE TOXICITY; BLEEDING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CHRONIC TOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETIC NEUROPATHY; DIARRHEA; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; EARLY MENOPAUSE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEADACHE; HERBAL MEDICINE; HOT FLUSH; HUMAN; MASTALGIA; MENOPAUSAL SYNDROME; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROTOXICITY; NONHUMAN; NUTRITIONAL STATUS; OSTEOLYSIS; OSTEOPOROSIS; OVARY INSUFFICIENCY; PATHOGENESIS; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY DISORDER; PREMATURE OVARIAN FAILURE; RADIATION SICKNESS; RASH; SECOND CANCER; SEIZURE THRESHOLD; STOMACH PAIN; TREATMENT OUTCOME; VERTIGO; VITAMIN SUPPLEMENTATION; VOMITING; WEIGHT GAIN;

ANGELICA SINENSIS; CAULOPHYLLUM; CIMICIFUGA DAHURICA; LETHRINIDAE; OENOTHERA; OENOTHERA BIENNIS; PRIMULA; TRIFOLIUM; TRIFOLIUM PRATENSE;

EID: 0242442493     PISSN: 00223166     EISSN: None     Source Type: Journal    
DOI: 10.1093/jn/133.11.3785s     Document Type: Conference Paper

References (114)

1. Isner, J. M., Ferrans, V. J., Cohen, S. R., Witkind, B. G., Virmani, R., Gottdiener, J. S., Beck, J. R. & Roberts, W. C. (1983) Clinical and morphologic cardiac findings after anthracycline chemotherapy. Analysis of 64 patients studied at necropsy. Am. J. Cardiol. 51: 1167-1174.
2. Von Hoff, D. D., Layard, M. W., Basa, P., Davis, H. L., Jr., Von Hoff, A. L., Rozencweig, M. & Muggia, F. M. (1979) Risk factors for doxorubucin-induced congestive heart failure. Ann. Intern. Med. 91: 710-717.
3. Allen, A. (1992) The cardiotoxicity of chemotherapeutic drugs. In: The Chemotherapy Sourcebook (Perry, M. C., ed.). Williams and Wilkins, Baltimore, MD.
4. Sparano, J. A. (1999) Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics. Semin. Oncol. 26: 14-19.
5. Seidman, A., Hudis, C., Pierri, M. K., Shak, S., Paton, V., Ashby, M., Murphy, M., Stewart, S. J. & Keefe, D. (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol. 20: 1215-1221.
6. Buzdar, A. U., Marcus, C., Smith, T. L. & Blumenschein, G. R. (1985) Early and delayed clinical cardiotoxicity of doxorubicin. Cancer 55: 2761-2765.
7. Lefrak, E. A., Pitha, J., Rosenheim, S. & Gottlieb, J. A. (1973) A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 32: 302-314.
8. Swain, S. M., Whaley, F. S. & Ewer, M. S. (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97: 2869-2879.
9. Billingham, M. E., Mason, J. W., Bristow, M. R. & Daniels, J. R. (1978) Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep. 62: 865-872.
10. Goormaghtigh, E., Huart, P., Praet, M., Brasseur, R. & Ruysschaert, J. M. (1990) Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity. Biophys. Chem. 35: 247-257.
11. Olson, R. D. & Mushlin, P. S. (1990) Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. FASEB J. 4: 3076-3086.
12. Gille, L. & Nohl, H. (1997) Analyses of the molecular mechanism of addamycin-induced cardiotoxicity. Free Radic. Biol. Med. 23: 775-782.
13. Horenstein, M. S., Vander Heide, R. S. & L'Ecuyer, T. J. (2000) Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol. Genet. Metab. 71: 436-444.
14. Grenier, M. A. & Lipshultz, S. E. (1998) Epidemiology of anthracycline cardiotoxicity in children and adults. Semin. Oncol. 25: 72-85.
15. Edwards, B. S., Hunt, S. A., Fowler, M. B., Valantine, H. A., Stinson, E. B. & Schroeder, J. S. (1990) Cardiac transplantation in patients with preexisting neoplastic diseases. Am. J. Cardiol. 65: 501-504.
16. Hensley, M. L., Schuchter, L. M., Lindley, C., Meropol, N. J., Cohen, G. I., Broder, G., Gradishar, W. J., Green, D. M., Langdon, R. J., Jr., Mitchell, R. B., Negrin, R., Szatrowski, T. P., Thigpen, J. T., Von Hoff, D., Wasserman, T. H., Winer, E. P. & Pfister, D. G. (1999) American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J. Clin. Oncol. 17: 3333-3355.
17. Singal, P. K., Siveski-Iliskovic, N., Hill, M., Thomas, T. P. & Li, T. (1995) Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J. Mol. Cell. Cardiol. 27: 1055-1063.
18. Kumar, N. B., Allen, K., Cantor, A., Cox, C. E., Greenberg, H., Shah, S. & Lyman, G. H. (1997) Weight gain associated with adjuvant tamoxifen therapy in stage I and II breast cancer: fact or artifact? Breast Cancer Res. Treat. 44: 135-143.
19. Shimpo, K., Nagatsu, T., Yamada, K., Sato, T., Niimi, H., Shamoto, M., Takeuchi, T., Umezawa, H. & Fujita, K. (1991) Ascorbic acid and adriamycin toxicity. Am. J. Clin. Nutr. 54: 1298S-1301S.
20. Myers, C. E., McGuire, W. & Young, R. (1976) Adriamycin: amelioration of toxicity by alpha-tocopherol. Cancer Treat. Rep. 60: 961-962.
21. Myers, C. E., McGuire, W. P., Liss, R. H., Ifrim, I., Grotzinger, K. & Young, R. C. (1977) Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 197: 165-167.
22. Tesoriere, L., Ciaccio, M., Valenza, M., Bongiorno, A., Maresi, E., Albiero, R. & Livrea, M. A. (1994) Effect of vitamin A administration on resistance of rat heart against doxorubicin-induced cardiotoxicity and lethality. J. Pharmacol. Exp. Ther. 269: 430-436.
23. Milei, J., Boveris, A., Llesuy, S., Molina, H. A., Storino, R., Ortega, D., Milei, S. E., Faber, M., Coudray, C., Hida, H., Mousseau, M., Favier, A., Ciaccio, M., Tesoriere, L., Pintaudi, A. M., Re, R., Vallesi-Cardillo, S., Bongiorno, A. & Livrea, M. A. (1986) Amelioration of adriamycin-induced cardiotoxicity in rabbits by prenylamine and vitamins A and E. Am. Heart J. 111: 95-102.
24. Faber, M., Coudray, C., Hida, H., Mousseau, M., Favier, A., Ciaccio, M., Tesoriere, L., Pintaudi, A. M., Re, R., Vallesi-Cardillo, S., Bongiomo, A. & Livrea, M. A. (1995) Lipid peroxidation products, and vitamin and trace element status in patients with cancer before and after chemotherapy, including adriamycin. A preliminary study. Biol. Trace Elem. Res. 47: 117-123.
25. Boucher, F., Coudray, C., Tirard, V., Barandier, C., Tresallet, N., Favier, A., de Leiris, J., Dimitrov, N. V., Hay, M. B., Siew, S., Hudler, D. A., Charamella, L. J., Ullrey, D. E., Chen, X. S., Xue, A., Morris, V. C., Ferrans, V. J., Herman, E. H., el-Hage, A., Levander, O. A. & Van Vleet, J. F. (1995) Oral selenium supplementation in rats reduces cardiac toxicity of adriamycin during ischemia and reperfusion. Nutrition 11: 708-711.
26. Dimitrov, N. V., Hay, M. B., Siew, S., Hudler, D. A., Charamella, L. J. & Ullrey, D. E. (1987) Abrogation of adriamycin-induced cardiotoxicity by selenium in rabbits. Am. J. Pathol. 126: 376-383.
27. Chen, X. S., Xue, A., Morris, V. C., Ferrans, V. J., Herman, E. H., el-Hage, A. & Levander, O. A. (1986) Effect of selenium deficiency on the chronic toxicity of adriamycin in rats. J. Nutr. 116: 2453-2465.
28. Legha, S. S., Wang, Y. M., Mackay, B., Ewer, M., Hortobagyi, G. N., Benjamin, R. S. & Ali, M. K. (1982) Clinical and pharmacologic investigation of the effects of alpha-tocopherol on adriamycin cardiotoxicity. Ann. N. Y. Acad. Sci. 393: 411-418.
29. Unverferth, D. V., Leier, C. V., Balcerzak, S. P. & Hamlin, R. L. (1985) Usefulness of a free radical scavenger in preventing doxorubicin-induced heart failure in dogs. Am. J. Cardiol. 56: 157-161.
30. Doroshow, J. H., Locker, G. Y., Ifrim, I. & Myers, C. E. (1981) Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine. J. Clin. Invest. 68: 1053-1064.
31. Myers, C., Bonow, R., Palmeri, S., Jenkins, J., Corden, B., Locker, G., Doroshow, J. & Epstein, S. (1983) A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin. Oncol. 10: 53-55.
32. Dresdale, A. R., Barr, L. H., Bonow, R. O., Mathisen, D. J., Myers, C. E., Schwartz, D. E., d'Angelo, T. & Rosenberg, S. A. (1982) Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin-induced cardiomyopathy. Am. J. Clin. Oncol. 5: 657-663.
33. Ohhara, H., Kanaide, H. & Nakamura, M. (1981) A protective effect of coenzyme Q10 on the adriamycin-induced cardiotoxicity in the isolated perfused rat heart. J. Mol. Cell. Cardiol. 13: 741-752.
34. Usui, T., Ishikura, H., Izumi, Y., Konishi, H., Dohmae, N., Sawada, H., Uchino, H., Matsuda, H., Konishi, T., Ohhara, H., Kanaide, H. & Nakamura, M. (1982) Possible prevention from the progression of cardiotoxicity in adriamycin-treated rabbits by coenzyme Q10. Toxicol. Lett. 12: 75-82.
35. Ronca-Testoni, S., Zucchi, R., Ronca, F., Bertelli, A., Usui, T., Ishikura, H., Izumi, Y., Konishi, H., Dohmae, N., Sawada, H., Uchino, H., Matsuda, H., Konishi, T., Ohhara, H., Kanaide, H. & Nakamura, M. (1992) Effect of carnitine and coenzyme Q10 on the calcium uptake in heart sarcoplasmic reticulum of rats treated with anthracyclines. Drugs Exp. Clin. Res. 18: 437-442.
36. Morishima, I., Matsui, H., Mukawa, H., Hayashi, K., Toki, Y., Okumura, K., Ito, T. & Hayakawa, T. (1998) Melatonin, a pineal hormone with antioxidant property, protects against adriamycin cardiomyopathy in rats. Life Sci. 63: 511-521.
37. Morishima, I., Okumura, K., Matsui, H., Kaneko, S., Numaguchi, Y., Kawakami, K., Mokuno, S., Hayakawa, M., Toki, Y., Ito, T. & Hayakawa, T. (1999) Zinc accumulation in adriamycin-induced cardiomyopathy in rats: effects of melatonin, a cardioprotective antioxidant. J. Pineal Res. 26: 204-210.
38. Kocak, G., Erbil, K. M., Ozdemir, I., Aydemir, S., Sunar, B., Tuncel, M. & Atalay, S. (2003) The protective effect of melatonin on adriamycin-induced acute cardiac injury. Can. J. Cardiol. 19: 535-541.
39. Das, D. K., Sato, M., Ray, P. S., Maulik, G., Engelman, R. M., Bertelli, A. A. & Bertelli, A. (1999) Cardioprotection of red wine: role of polyphenolic antioxidants. Drugs Exp. Clin. Res. 25: 115-120.
40. Bagchi, D., Sen, C. K., Ray, S. D., Das, D. K., Bagchi, M., Preuss, H. G. & Vinson, J. A. (2003) Molecular mechanisms of cardioprotection by a novel grape seed proanthocyanidin extract. Mutat. Res. 523-524: 87-97.
41. Bagchi, D., Bagchi, M., Stohs, S., Ray, S. D., Sen, C. K. & Preuss, H. G. (2002) Cellular protection with proanthocyanidins derived from grape seeds. Ann. N. Y. Acad. Sci. 957: 260-270.
42. Bergman, M., Perelman, A., Dubinsky, Z., Grossman, S., Breitbart, E., Lomnitski, L., Nyska, A., Malik, Z., Sofer, Y., Haseman, J. K., Varshavsky, L. & Gottlieb, H. E. (2003) Scavenging of reactive oxygen species by a novel glucurinated flavonoid antioxidant isolated and purified from spinach. Phytochemistry 62: 753-762.
43. Breitbart, E., Lomnitski, L., Nyska, A., Malik, Z., Bergman, M., Sofer, Y., Haseman, J. K. & Grossman, S. (2001) Effects of water-soluble antioxidant from spinach, NAO, on doxorubicin-induced heart injury. Hum. Exp. Toxicol. 20: 337-345.
44. Van Acker, S. A., Boven, E., Kuiper, K., Van den Berg, D. J., Grimbergen, J. A., Kramer, K., Bast, A. & Van der Vijgh, W. J. (1997) Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin. Cancer Res. 3: 1747-1754.
45. Van Acker, F. A., Hulshof, J. W., Haenen, G. R., Menge, W. M., Van der Vijgh, W. J. & Bast, A. (2001) New synthetic flavonoids as potent protectors against doxorubicin-induced cardiotoxicity. Free Radic. Biol. Med. 31: 31-37.
46. Rowinsky, E. K. & Donehower, R. C. (1995) Paclitaxel (taxol). N. Engl. J. Med. 332: 1004-1014.
47. Forsyth, P. A., Balmaceda, C., Peterson, K., Seidman, A. D., Brasher, P. & DeAngelis, L. M. (1997) Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J. Neurooncol. 35: 47-53.
48. Hilkens, P. H., Verweij, J., Stoter, G., Vecht, C. J., Van Putten, W. L. & Van den Bent, M. J. (1996) Peripheral neurotoxicity induced by docetaxel. Neurology 46: 104-108.
49. Michaud, L. B., Valero, V. & Hortobagyi, G. (2000) Risks and benefits of taxanes in breast and ovarian cancer. Drug Saf. 23: 401-428.
50. Postma, T. J., Vermorken, J. B., Liefting, A. J., Pinedo, H. M. & Heimans, J. J. (1995) Paclitaxel-induced neuropathy. Ann. Oncol. 6: 489-494.
51. Rowinsky, E. K. & Donehower, R. C. (1991) The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol. Ther. 52: 35-84.
52. Ohtsu, T., Sasaki, Y., Tamura, T., Miyata, Y., Nakanomyo, H., Nishiwaki, Y. & Saijo, N. (1995) Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin. Cancer Res. 1: 599-606.
53. Postma, T. J., Heimans, J. J., Muller, M. J., Ossenkoppele, G. J., Vermorken, J. B. & Aaronson, N. K. (1998) Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann. Oncol. 9: 739-744.
54. Mendell, J. R. & Sahenk, Z. (2003) Clinical practice. Painful sensory neuropathy. N. Engl. J. Med. 348: 1243-1255.
55. Cassidy, J., Paul, J., Soukop, M., Habeshaw, T., Reed, N. S., Parkin, D. & Kaye, S. B. (1998) Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother. Pharmacol. 41: 161-166.
56. Roberts, J. A., Jenison, E. L., Kim, K., Clarke-Pearson, D. & Langleben, A. (1997) A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecol. Oncol. 67: 172-177.
57. Cascinu, S., Cordella, L., Del Ferro, E., Fronzoni, M. & Catalano, G. (1995) Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J. Clin. Oncol. 13: 26-32.
58. Pronk, L. C., Hilkens, P. H., Van den Bent, M. J., Van Putten, W. L., Stoter, G. & Verweij, J. (1998) Corticosteroid co-medication does not reduce the incidence and severity of neurotoxicity induced by docetaxel. Anticancer Drugs 9: 759-764.
59. Sindrup, S. H. & Jensen, T. S. (2000) Pharmacologic treatment of pain in polyneuropathy. Neurology 55: 915-920.
60. Morello, C. M., Leckband, S. G., Stoner, C. P., Moorhouse, D. F. & Sahagian, G. A. (1999) Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch. Intern. Med. 159: 1931-1937.
61. Rull, J. A., Quibrora, R., Gonzalez-Millan, H. & Lozano Castaneda, O. (1969) Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia 5: 215-218.
62. Sindrup, S. H., Gram, L. F., Brosen, K., Eshoj, O. & Mogensen, E. F. (1990) The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 42: 135-144.
63. Sindrup, S. H., Bjerre, U., Dejgaard, A., Brosen, K., Aaes-Jorgensen, T. & Gram, L. F. (1992) The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy. Clin. Pharmacol. Ther. 52: 547-552.
64. Tasmuth, T., Hartel, B. & Kalso, E. (2002) Venlafaxine in neuropathic pain following treatment of breast cancer. Eur. J. Pain 6: 17-24.
65. Semenchuk, M. R., Sherman, S. & Davis, B. (2001) Double-blind, randomized trial of bupropion SR for the treatment of neuropathic pain. Neurology 57: 1583-1588.
66. Halat, K. M. & Dennehy, C. E. (2003) Botanicals and dietary supplements in diabetic peripheral neuropathy. J. Am. Board Fam. Pract. 16: 47-57.
67. Jamal, G. A. & Carmichael, H. (1990) The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Diabet. Med. 7: 319-323.
68. Jamal, G. A. (1994) The use of gamma linolenic acid in the prevention and treatment of diabetic neuropathy. Diabet. Med. 11: 145-149.
69. Purewal, T. S., Evans, P. M. S., Havard, F. & O'Hare, J. P. (1997) Lack of effect of evening primrose oil on autonomic function tests after 12 months of treatment. Diabetologia 40: 556 (abs).
70. Moini, H., Packer, L. & Saris, N. E. (2002) Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid. Toxicol. Appl. Pharmacol. 182: 84-90.
71. Ruhnau, K. J., Meissner, H. P., Finn, J. R., Reljanovic, M., Lobisch, M., Schutte, K., Nehrdich, D., Tritschler, H. J., Mehnert, H. & Ziegler, D. (1999) Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet. Med. 16: 1040-1043.
72. Reljanovic, M., Reichel, G., Rett, K., Lobisch, M., Schuette, K., Moller, W., Tritschler, H. J. & Mehnert, H. (1999) Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic. Res. 31: 171-179.
73. Ziegler, D., Hanefeld, M., Ruhnau, K. J., Hasche, H., Lobisch, M., Schutte, K., Kerum, G. & Malessa, R. (1999) Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 22: 1296-1301.
74. Gedlicka, C., Kornek, G. V., Schmid, K. & Scheithauer, W. (2003) Amelioration of docetaxel/cisplatin induced polyneuropathy by alphalipoic acid. Ann. Oncol. 14: 339-340.
75. Forst, T., Pohlmann, T., Kunt, T., Goitom, K., Schulz, G., Lobig, M., Engelbach, M., Beyer, J. & Pfutzner, A. (2002) The influence of local capsaicin treatment on small nerve fibre function and neurovascular control in symptomatic diabetic neuropathy. Acta Diabetol. 39: 1-6.
76. Scheffler, N. M., Sheitel, P. L. & Lipton, M. N. (1991) Treatment of painful diabetic neuropathy with capsaicin 0.075%. J. Am. Podiatr. Med. Assoc. 81: 288-293.
77. Tandan, R., Lewis, G. A., Krusinski, P. B., Badger, G. B. & Fries, T. J. (1992) Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Diabetes Care 15: 8-14.
78. Low, P. A., Opfer-Gehrking, T. L., Dyck, P. J., Litchy, W. J. & O'Brien, P. C. (1995) Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. Pain 62: 163-168.
79. Lower, E. E., Blau, R., Gazder, P. & Tummala, R. (1999) The risk of premature menopause induced by chemotherapy for early breast cancer. J. Womens Health Gender Based Med. 8: 949-954.
80. Meirow, D. & Nugent, D. (2001) The effects of radiotherapy and chemotherapy on female reproduction. Hum. Reprod. Update 7: 535-543.
81. Burstein, H. & Winer, E. (2000) Primary care for survivors of breast cancer. N. Engl. J. Med. 343: 1086-1094.
82. Blumenfeld, Z., Avivi, I., Ritter, M. & Rowe, J. M. (1999) Preservation of fertility and ovarian function and minimizing chemotherapy-induced gonadotoxicity in young women. J. Soc. Gynecol. Investig. 6: 229-239.
83. Chlebowski, R. T., Hendrix, S. L., Langer, R. D., Stefanick, M. L., Gass, M., Lane, D., Rodabough, R. J., Gilligan, M. A., Cyr, M. G., Thomson, C. A., Khandekar, J., Petrovitch, H., McTiernan, A. & W. H. I. Investigators (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289: 3243-3253.
84. Wassertheil-Smoller, S., Hendrix, S. L., Limacher, M., Heiss, G., Kooperberg, C., Baird, A., Kotchen, T., Curb, J. D., Black, H., Rossouw, J. E., Aragaki, A., Safford, M., Stein, E., Laowattana, S., Mysiw, W. J. & W. H. I. Investigators (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 289: 2673-2684.
85. Rapp, S. R., Espeland, M. A., Shumaker, S. A., Henderson, V. W., Brunner, R. L., Manson, J. E., Gass, M. L., Stefanick, M. L., Lane, D. S., Hays, J., Johnson, K. C., Coker, L. H., Dailey, M., Bowen, D. & W. H. I. M. S. Investigators (2003) Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289: 2663-2672.
86. Shumaker, S. A., Legault, C., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones, B. N., 3rd, Assaf, A. R., Jackson, R. D., Kotchen, J. M., Wassertheil-Smoller, S., Wactawski-Wende, J. & W. H. I. M. S. Investigators (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289: 2651-2662.
87. Hays, J., Ockene, J. K., Brunner, R. L., Kotchen, J. M., Manson, J. E., Patterson, R. E., Aragaki, A. K., Shumaker, S. A., Brzyski, R. G., LaCroix, A. Z., Granek, I. A., Valanis, B. G. & Women's Health Initiative Invesitgators (2003) Effects of estrogen plus progestin on health-related quality of life. N. Engl. J. Med. 348: 1839-1854.
88. Beckmann, M. W., Jap, D., Djahansouzi, S., Nestle-Kramling, C., Kuschel, B., Dall, P., Brumm, C. & Bender, H. G. (2001) Hormone replacement therapy after treatment of breast cancer: effects on postmenopausal symptoms, bone mineral density and recurrence rates. Oncology. 60: 199-206.
89. DiSaia, P. J., Grosen, E. A., Kurosaki, T., Gildea, M., Cowan, B. & Anton-Culver, H. (1996) Hormone replacement therapy in breast cancer survivors: a cohort study. Am. J. Obstet. Gynecol. 174: 1494-1498.
90. Seibel, M. M. (2003) Treating hot flushes without hormone replacement therapy. J. Fam. Pract. 52: 291-296.
91. Jacobson, J. S., Troxel, A. B., Evans, J., Klaus, L., Vahdat, L., Kinne, D., Lo, K. M., Moore, A., Rosenman, P. J., Kaufman, E. L., Neugut, A. I. & Grann, V. R. (2001) Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J. Clin. Oncol. 19: 2739-2745.
92. Stoll, W. (1987) Phytopharmacon influences atrophic vaginal epithelium: double blind study-Cimicifuga vs. estrogenic stubstances. Therapeuticum 1: 23-31.
93. Vitetta, L., Thomsen, M. & Sali, A. (2003) Black cohosh and other herbal remedies associated with acute hepatitis. Med. J. Aust. 178: 411-412.
94. Huntley, A. & Ernst, E. (2003) A systematic review of the safety of black cohosh. Menopause 10: 58-64.
95. Mahady, G. B., Fabricant, D., Chadwick, L. R. & Dietz, B. (2002) Black cohosh: an alternative therapy for menopause? Nutr. Clin. Care. 5: 283-289.
96. Hirata, J. D., Swiersz, L. M., Zell, B., Small, R. & Ettinger, B. (1997) Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil. Steril. 68: 981-986.
97. Liu, J., Burdette, J. E., Xu, H., Gu, C., Van Breemen, R. B., Bhat, K. P., Booth, N., Constantinou, A. I., Pezzuto, J. M., Fong, H. H., Farnsworth, N. R. & Bolton, J. L. (2001) Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J. Agric. Food Chem. 49: 2472-2479.
98. Page, R. L., 2nd & Lawrence, J. D. (1999) Potentiation of warfarin by dong quai. Pharmacotherapy 19: 870-876.
99. Chenoy, R., Hussain, S., Tayob, Y., O'Brien, P. M., Moss, M. Y. & Morse, P. F. (1994) Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. BMJ 308: 501-503.
100. Baber, R., Templeman, C., Moreton, T., Kelly, G. & West, L. (1999) Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric 2: 85-92.
101. Knight, D., Howes, J. & Eden, J. (1999) The effect of Promensil, an isoflavone extract, on menopausal symptoms. Climacteric 2: 79-84.
102. Tice, J., Ettinger, B., Ensrud, K., Wallace, R., Blackwell, T. & Cummings, S. (2003) Phytoestrogen supplements for the treatment of hot flashes: the isoflavon clover extract (ICE) study. JAMA 290: 207-214.
103. Barton, D. L., Loprinzi, C. L., Quella, S. K., Sloan, J. A., Veeder, M. H., Egner, J. R., Fidler, P., Stella, P. J., Swan, D. K., Vaught, N. L. & Novotny, P. (1998) Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J. Clin. Oncol. 16: 495-500.
104. Eastell, R. (1998) Treatment of postmenopausal osteoporosis. N. Engl. J. Med. 338: 736-746.
105. Pfeilschifter, J. & Diel, I. J. (2000) Osteoporosis due to cancer treatment: pathogenesis and management. J. Clin. Oncol. 18: 1570-1593.
106. Shapiro, C. L., Manola, J. & Leboff, M. (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J. Clin. Oncol. 19: 3306-3311.
107. Headley, J. A., Theriault, R. L., LeBlanc, A. D., Vassilopoulou-Sellin, R. & Hortobagyi, G. N. (1998) Pilot study of bone mineral density in breast cancer patients treated with adjuvant chemotherapy. Cancer Invest. 16: 6-11.
108. Saarto, T., Blomqvist, C., Valimaki, M., Makela, P., Sarna, S. & Elomaa, I. (1997) Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J. Clin. Oncol. 15: 1341-1347.
109. Powles, T. J. (1998) Status of antiestrogen breast cancer prevention trials. Oncology 12: 28-31.
110. Delmas, P. D., Balena, R., Confravreux, E., Hardouin, C., Hardy, P. & Bremond, A. (1997) Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J. Clin. Oncol. 15: 955-962.
111. Ettinger, B., Black, D. M., Mitlak, B. H., Knickerbocker, R. K., Nickelsen, T., Genant, H. K., Christiansen, C., Delmas, P. D., Zanchetta, J. R., Stakkestad, J., Gluer, C. C., Krueger, K., Cohen, F. J., Eckert, S., Ensrud, K. E., Avioli, L. V., Lips, P. & Cummings, S. R. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282: 637-645.
112. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, & Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA. 285: 785-795.
113. Prentice, A. (2002) What are the dietary requirements for calcium and vitamin D? Calcif. Tissue Int. 70: 83-88.
114. Snow-Harter, C., Bouxsein, M. L., Lewis, B. T., Carter, D. R. & Marcus, R. (1992) Effects of resistance and endurance exercise on bone mineral status of young women: a randomized exercise intervention trial. J. Bone Miner. Res. 7: 761-769.